Litigation Details for AstraZeneca AB v. Watson Laboratories Inc. (D. Del. 2014)
✉ Email this page to a colleague
AstraZeneca AB v. Watson Laboratories Inc. (D. Del. 2014)
| Docket | ⤷ Sign Up | Date Filed | 2014-05-23 |
| Court | District Court, D. Delaware | Date Terminated | 2015-04-16 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | Defendant | Referred To | |
| Patents | 7,951,400; RE44,186 | ||
| Link to Docket | External link to docket | ||
Details for AstraZeneca AB v. Watson Laboratories Inc. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2014-05-23 | 1 | product, prior to expiration of U.S. Patent No. 7,951,400 (“the ’400 patent”). ME1 17953993v.2 Case … This is an action for patent infringement arising under the patent laws of the United States, … PATENT-IN-SUIT 17. On May 31, 2011, the U.S. Patent and Trademark Office…copy of the ’400 patent is attached hereto as Exhibit A. The claims of the ’400 patent are valid and enforceable…includes ONGLYZA® together with the ’400 patent and U.S. Patent No. RE44,186, which covers the composition | External link to document | |
| 2014-09-23 | 16 | than April 10, 2014. Date of Expiration of Patent: 7,951,400 (November 30, 2028).Thirty Month Stay Deadline… Amended Supplemental information for patent cases involving an Abbreviated New Drug Application…2014 16 April 2015 1:14-cv-00666 830 Patent Defendant District Court, D. Delaware | External link to document | |
| 2014-05-23 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,951,400. (rwc) (Entered: 05…2014 16 April 2015 1:14-cv-00666 830 Patent Defendant District Court, D. | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
